Search Results - "Carr, Molly"

The Emergence of the Metabolic Syndrome with Menopause by Carr, Molly C.

“…Women with the metabolic syndrome (central obesity, insulin resistance, and dyslipidemia) are known to be at especially high risk for cardiovascular disease…”
Get full text

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial by Rosenstock, Julio, Nino, Antonio, Soffer, Joseph, Erskine, Lois, Acusta, Andre, Dole, Jo, Carr, Molly C, Mallory, Jason, Home, Philip

“…The principle of replacing prandial insulin lispro with a once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) for type 2 diabetes inadequately…”
Get full text

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea by Weissman, Peter N., Carr, Molly C., Ye, June, Cirkel, Deborah T., Stewart, Murray, Perry, Caroline, Pratley, Richard

“…Aims/hypothesis The aim of this study was to compare the efficacy and safety of once-weekly albiglutide with once-daily insulin glargine (A21Gly,B31Arg,B32Arg…”
Get full text

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial by Bergenstal, Richard M, Weinstock, Ruth S, Mathieu, Chantal, Onishi, Yukiko, Vijayanagaram, Vishali, Katz, Michelle L, Carr, Molly C, Chang, Annette M

“…Insulin efsitora alfa (efsitora) is a once-weekly basal insulin. This phase 3 study aimed to assess the efficacy and safety of efsitora compared with insulin…”
Get full text

Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study by Leiter, Lawrence A, Carr, Molly C, Stewart, Murray, Jones-Leone, Angela, Scott, Rhona, Yang, Fred, Handelsman, Yehuda

“…To evaluate weekly subcutaneous albiglutide versus daily sitagliptin in renally impaired patients with type 2 diabetes and inadequately controlled glycemia on…”
Get full text

Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment by Wysham, Carol, Bajaj, Harpreet S, Del Prato, Stefano, Franco, Denise Reis, Kiyosue, Arihiro, Dahl, Dominik, Zhou, Chunmei, Carr, Molly C, Case, Michael, Firmino Gonçalves, Livia

“…Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase…”
Get full text

Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk by Carr, Molly C., Brunzell, John D.

“…Regional body fat distribution has an important influence on metabolic and cardiovascular risk factors. Increased abdominal (visceral) fat accumulation is a…”
Get full text

Adipokines, Inflammation, and Visceral Adiposity across the Menopausal Transition: A Prospective Study by Lee, Christine G., Carr, Molly C., Murdoch, Susan J., Mitchell, Ellen, Woods, Nancy F., Wener, Mark H., Chandler, Wayne L., Boyko, Edward J., Brunzell, John D.

“…Context: Postmenopausal women have greater visceral adiposity compared with premenopausal women. Adipokines are associated with increased adiposity, insulin…”
Get full text

Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme by Bergenstal, Richard M., Philis‐Tsimikas, Athena, Wysham, Carol, Carr, Molly C., Bue‐Valleskey, Juliana M., Botros, Fady T., Blevins, Thomas, Rosenstock, Julio

“…Aims Insulin efsitora alfa (efsitora) is a once‐weekly basal insulin. This review describes the study design and rationale of the efsitora phase 3 Once Weekly…”
Get full text

Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure by Verdino, Petra, Lee, Stacey L., Cooper, Fariba N., Cottle, Steven R., Grealish, Patrick F., Hu, Charlie C., Meyer, Catalina M., Lin, Joanne, Copeland, Victoria, Porter, Gina, Schroeder, Richard L., Thompson, Tyran D., Porras, Leah L., Dey, Asim, Zhang, Hong Y., Beebe, Emily C., Matkovich, Scot J., Coskun, Tamer, Balciunas, Aldona M., Ferrante, Andrea, Siegel, Robert, Malherbe, Laurent, Bivi, Nicoletta, Paavola, Chad D., Hansen, Ryan J., Abernathy, Matthew M., Nwosu, Sylvia O., Carr, Molly C., Heuer, Josef G., Wang, Xiaojun

“…Background and Purpose Chronic heart failure, a progressive disease with limited treatment options currently available, especially in heart failure with…”
Get full text

Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies by Turgeon, Judith L, Carr, Molly C, Maki, Pauline M, Mendelsohn, Michael E, Wise, Phyllis M

“…Recent publications describing the results of the Women’s Health Initiative (WHI) and other studies reporting the impact of hormone therapy on aging women have…”
Get full text

Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials by Ahrén, Bo, Carr, Molly C, Murphy, Karen, Perkins, Christopher, Rendell, Marc, Mallory, Jason, Wilson, Timothy, Johnson, Susan

“…Highlights • Integrated safety analysis from albiglutide phase 3 trials of up to 3 years length. • Frequency of overall AEs was similar between albiglutide and…”
Get full text

Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy by Home, Philip D, Ahrén, Bo, Reusch, Jane E.B, Rendell, Marc, Weissman, Peter N, Cirkel, Deborah T, Miller, Diane, Ambery, Philip, Carr, Molly C, Nauck, Michael A

“…Highlights • Efficacy results from five 3-year, phase 3 trials of the GLP-1RA albiglutide. • Less hyperglycaemic rescue needed with albiglutide vs placebo ( p…”
Get full text

Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs by Okuda, Inaha, Wilson, Timothy H., Yue, Lin, Nakajima, Hiromu, Carr, Molly C., Tsuboi, Maho, Nino, Antonio, Seino, Yutaka

“…Objective: To evaluate the safety and efficacy of once weekly albiglutide added to a single oral antidiabetic drug (OAD) in Japanese patients with inadequately…”
Get full text

Weekly glucagon‐like peptide‐1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled study by Nino, Antonio, Okuda, Inaha, Wilson, Timothy H, Yue, Lynn, Nakajima, Hiromu, Tsuboi, Maho, Carr, Molly C, Seino, Yutaka

“…Aims/Introduction The present phase 3, randomized, double‐blind 24‐week study with extension to 1 year assessed the efficacy and safety of albiglutide compared…”
Get full text

Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet by Deeb, Samir S, Zambon, Alberto, Carr, Molly C, Ayyobi, Amir F, Brunzell, John D

“…Hepatic lipase (HL) plays a central role in LDL and HDL remodeling. High HL activity is associated with small, dense LDL particles and with reduced HDL2…”
Get full text

Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes by Matthews, Jessica E., Reinhardt, Rickey R., Carr, Molly C.

“…Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) vary in their structure, duration of action, efficacy, and safety. In order to optimize glycemic control,…”
Get full text

Independent community pharmacist interest in participating in community pharmacy research networks by Carr, Molly B., PharmD, MBA, Divine, Holly, PharmD, CGP, CDE, Hanna, Cathy, PharmD, Freeman, Patricia R., PhD, Blumenschein, Karen, PharmD

“…Objectives To assess the interest of American Pharmacy Services Corporation (APSC) independent community pharmacists in participating in a community pharmacy…”
Get full text

Increased urinary cortisol levels during the menopausal transition by Woods, Nancy F, Carr, Molly C, Tao, Eunice Y, Taylor, Heather J, Mitchell, Ellen S

“…To determine whether cortisol levels change prospectively during the menopausal transition (MT); whether these changes are associated with changes in the…”
Get full text

Varying cost and free Nicotinic acid content in over-the-counter niacin preparations for dyslipidemia by MEYERS, C. Daniel, CARR, Molly C, PARK, Sang, BRUNZELL, John D

“…Nicotinic acid is an effective treatment for dyslipidemia, but the content of over-the-counter niacin is not federally regulated. As a result, patients may use…”
Get full text